Amedisys, Inc. announced that it is now offering advanced molecular testing to its care centers nationwide. This innovative collaboration with Patient Choice Laboratories utilizes molecular testing for the swift and precise identification of pathogens in urine, respiratory and wound infections. By leveraging the latest in diagnostic technology, Amedisys aims to improve the quality of infection testing, ultimately facilitating better patient care and outcomes.

Advanced molecular testing revolutionizes the diagnosis and management of infections, as it delivers rapid and precise results, ultimately enabling quicker initiation of appropriate treatment interventions. With improved accuracy, sensitivity and specificity, molecular testing significantly enhances the ability to identify infectious pathogens, supporting timely and targeted care strategies. Amedisys has implemented comprehensive protocols and training to ensure seamless integration of molecular testing into its care centers.

The rollout of this innovative approach to infection diagnosis underscores the organization?s commitment to staying at the forefront of healthcare advancements and technology, ultimately providing its patients with the highest standard of care and support.